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CObjectives: Therapy for osteoporosis reduces the risk of fracture in
clinical trials; real-world adherence to therapy is suboptimal and
may reduce the effectiveness of intervention. The objective was to
assess the fracture risk among patients nonadherent versus adher-
ent to therapy for osteoporosis. Methods: Medline, Embase, and
INAHL were searched for English-language publications of obser-
ational studies (January 1998 –February 2009). Proceedings from
wo recent meetings of five relevant conferences were hand
earched. Prospective and retrospective observational studies of pa-
ients with osteoporosis receiving bisphosphonates, parathyroid
ormone, or selective estrogen receptor modulators denosumab
ere included. Studies were required to consider both fracture risk
nd adherence (compliance and/or persistence); any definition of
dherence/fracture was acceptable. Data were analyzed using
ooled comparisons of the odds and hazard ratios of fracture in
oncompliance versus compliance and nonpersistence versus per-
istence. Sensitivity analyses were conducted to determine the ef- O
asse
al So
doi:10.1016/j.jval.2010.11.010ect of clinical heterogeneity on the results. Results: Twenty-seven
itations were identified, the majority of which were retrospective data-
ase analyses considering the effect of adherence to bisphosphonate
herapy on fracture at any skeletal site. The absolute frequency of fracture
anged from 6% to 38% with noncompliance and from 5% to 19% with
onpersistence (104–159 weeks). Meta-analysis indicates that fracture
isk increases by approximately 30% with noncompliance (odds ratio [95%
onfidence interval] 1.29 [1.22–1.38]; hazard ratio 1.28 [1.18–1.38]) and by
0% to 40% with nonpersistence (odds ratio 1.40 [1.29–1.52]; hazard ratio
.32 [1.23–1.42]). Conclusions: Poor medication adherence is associated
ith a significantly increased risk of fracture versus optimal adher-
nce. Improving medication adherence in patients with osteoporosis
ay lead to a greater reduction in fracture.
eywords: adherence, compliance, fracture, meta-analysis, osteoporo-
is.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Osteoporosis, a skeletal disorder characterized by reductions in bone
mass (estimated by measurement of bone mineral density) and bone
quality, is associated with an increased frequency of fractures. Os-
teoporosis-related fractures represent a significant burden on society
in terms of severe morbidity, increased mortality, and high health
care expenditures [1]. In the United States alone there are as many as
8 million women and 2 million men with osteoporosis [1], which is
estimated to result in at least 1.5 million fractures per year [2] costing
approximately $19 billion [3]. It is predicted that this will increase to
more than 3 million fractures at a cost of approximately $25.3 billion
by 2025 [4]. The high incidence of fracture within the population with
osteoporosis is therefore an important focus for preventative action.
The 2004US Surgeon General’s Report on Bone Health and Osteoporosis [5]
notes that preventative action is needed to reduce fractures experi-
enced by older individuals to reduce both the human and economic
costs of this public health problem.
The current pharmacologic management of osteoporosis in the
United States includes the use of bisphosphonates, selective estro-
gen receptor modulators denosumab, intranasal calcitonin, and the
* Address correspondence to: Susan Ross, SD Ross Consulting, Coh
E-mail address: sdross720@gmail.com.
1098-3015/$36.00 – see front matter Copyright © 2011, Internation
Published by Elsevier Inc.anabolic agent teriparatide (human recombinant parathyroid hor-
mone 1–34). Hormone therapy is approved for the prevention of os-
teoporosis. These drug treatments have been shown to increase bone
mass and significantly reduce the risk of fracture in clinical trials
[6–11]. However, real-world adherence, comprising compliance (“the
extent to which a patient acts in accordance with the prescribed
interval and dose of a dosing regimen” [12]) and persistence (“the
duration of time from initiation to discontinuation of therapy” [12]),
associated with such prescribed medication is suboptimal and may
reduce the effectiveness of these interventions. Indeed, it is esti-
mated that between one-third and one-half of patients do not take
their medication as directed [13].
Poor adherence has been associated with increased fracture risk
and increased frequency of hospitalization and other resource use in
comparison with optimal adherence [14–16]. In a qualitative review
of the literature, Siris et at. [17] conclude that an increased risk of
fracture with poor adherence to osteoporosis medication can be ob-
served across a range of studies investigating a variety of medica-
tions and fracture locations. Although the definitions of adherence
were varied, the most common measure of compliance reported was
the Medication Possession Ratio (MPR), defined as the sum of the
t, MA, USA.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
572 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 5 7 1 – 5 8 1days’ supply of medication divided by the number of days between
the first fill and the last refill plus the days’ supply of the last refill [18],
while the most frequently used measure of persistence was the ab-
sence of a prescription refill over a duration exceeding 30 days.
Recently, a systematic review and meta-analysis has been pub-
lished that measures the degree of compliance and persistence with
bisphosphonate therapy [19]. The authors of that publication also
present a quantitative analysis of the effects of compliance to bis-
phosphonate therapy on the risk of fracture. Although it appears that
their systematic review was not designed specifically to identify
studies presenting data on the risk of fracture with noncompliance,
the analysis of the included studies reporting such data suggests that
there is an increase in fracture risk with noncompliance compared to
compliance. However, no systematic review of the literature con-
ducted to date has been specifically designed to quantitatively ana-
lyze the increase in fracture risk associated with nonadherence (non-
compliance and/or nonpersistence) versus optimal adherence
(compliance and/or persistence) through meta-analysis. Specifically,
the quantitative increase in fracture risk with nonpersistence com-
pared to persistence has not been addressed.
Therefore, our systematic review was designed to assess the
magnitude of fracture risk in a nonadherent compared to an adher-
ent osteoporosis patient population, using meta-analytic tech-
niques. It was hypothesized that individuals with osteoporosis who
were nonadherent to their prescribed medication would experience
a greater incidence of fracture than patients who were adherent to
therapy. A secondary aim was to determine the predictors of adher-
ence, as well as the risk of hospitalization and the change in direct
costs associated with fracture in the nonadherent versus adherent
osteoporosis population, as identified within the included studies.
Methods
Data sources
Medline, Embase, and CINAHL were searched from January 1,
1998, to February 17, 2009, for English-language publications of
observational studies. Standard filters developed by the Scottish
Intercollegiate Guidance Network [20] were used to search for
study design (observational study), while clinical keywords and
medical subject headings were used to search for disease (“osteo-
porosis”) and outcome (“adherence” and “fracture”). An example
search strategy is presented as supplementary material; all fur-
ther search strategies used are available upon request. In addition,
the proceedings from the two most recent meetings of five rele-
vant symposia were hand-searched (European Symposium on
Calcified Tissue International 2007 and 2008; International Sym-
posium on Osteoporosis 2007 and 2008; European Congress on
Clinical and Economic Aspects of Osteoporosis and Osteoarthritis
2008 and 2009; American Society for Bone and Mineral Research
2007 and 2008; International Bone and Mineral Society Scientific
Meeting 2007 and 2009). The conference proceedings from the In-
ternational Osteoporosis Foundation World Osteoporosis Con-
gress were not searched due to the cancellation of the 2008 con-
gress. Finally, the bibliographies of all included studies were
reviewed to identify any studies not retrieved through the data-
base search. No efforts were made to contact authors.
Study eligibility
Studies with an observational design (case-control, cohort, or
cross-sectional), both retrospective and prospective, and pub-
lished in English from January 1998 to February 2009 were in-
cluded in the review. Studies were not excluded on the basis of
follow-up duration. Given the rapidly evolving treatment options
for patients with osteoporosis, studies published before 1998 were
considered unlikely to contain information relevant to the currentclinical situation. Similarly, randomized controlled trials are as-
sumed to not accurately reflect real-world clinical practice and so
were not included in the review.
The patients of interest were those with evidence of osteopo-
rosis (as assessed by the individual study investigators; for exam-
ple, patients identified through the use of osteoporosis-related
ICD-9 or ICD-10 codes) and treatment with a qualifying osteopo-
rosis medication (bisphosphonate, parathyroid hormone, or selec-
tive estrogen receptor modulators). The identified studies were
required to consider both fracture risk and adherence to be in-
cluded. Any clinical definition of compliance/persistence (e.g.,
MPR, treatment refill gap  30 days, but not self-reported adher-
ence) and fracture (e.g., osteoporosis-related and identified using
ICD-9 or ICD-10 codes or through radiological documentation, but
not self-reported fracture) used by the authors was acceptable for
inclusion into the systematic review; stricter criteria were used to
determine inclusion into the pooled quantitative analyses (see be-
low).
The included population was originally restricted to female
post-menopausal osteoporosis (PMO) patients aged 45 years and
older; a protocol amendment expanded this population to include
studies of both male and female patients of any age receiving ther-
apy with an osteoporosis medication. The planned PMO cohort
analysis thus became a subgroup analysis secondary to the main
research question. The a priori protocol is available upon request.
Study selection
Bibliographic details and abstracts of all citations detected by the
literature search were downloaded into the Heron Systematic Re-
view Database, a bespoke, SQL-based Internet database. A team of
reviewers—information scientists specializing in evidence-based
medicine—independently determined the eligibility of each pub-
lication by applying the defined set of selection criteria (see above).
Two different reviewers considered each publication, with dis-
crepancies resolved by a third reviewer. Citations were first
screened based on the abstract supplied with each citation. Full-
text copies of all references that might meet the eligibility criteria
were ordered alongside those where it was not possible to exclude
or include based on the abstract. The eligibility criteria were ap-
plied to the full-text citations in a second pass of the studies.
Data extraction
Two reviewers extracted data from eligible publications in paral-
lel; a third reviewer checked the resulting extractions and resolved
any discrepancies through team discussion. Only one extraction
dataset per study was compiled from all publications relating to
that study so as to avoid the error of double-counting patients in
subsequent analyses. Data extracted included study design; pa-
tient population characteristics; fracture rate by level of adher-
ence; and odds, hazard, and risk ratio data relating to fracture risk
and nonadherence/adherence.
Quality scoring of observational studies is controversial be-
cause the constructs may not be valid or represent the actual qual-
ity of the study [21]. Instead, key aspects of design are important
considerations in the assessment of study quality. As such, each
study was subject to a qualitative critical appraisal of quality at the
time of data abstraction using a project-specific assessment of
quality (risk of bias). This assessment was made for each publica-
tion based upon the existence of a study question, the methodol-
ogy employed to answer the study question, the appropriateness
of the defined population and the data collection methods used,
the clarity in the presentation of results and statistical analyses
conducted (including consideration of confounding factors), and
the reliability of the conclusions drawn. Although the questions
are subjective, they give an overall indication of the strengths and
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validity of pooling the results in a meta-analysis.
Quantitative data synthesis
Pooled direct comparisons were made using conventional meta-
analysis techniques. When conducting the meta-analyses, Stata
statistical software was used to run the metan meta-analysis com-
mand, where the Mantel-Haenszel method is used to weight the
studies [22]. The following meta-analyses were conducted:
● Odds ratio for fracture in noncompliant (MPR  80%) versus
compliant (MPR  80%) patients;
● Hazard ratio for fracture in non-compliant (MPR  80%) versus
compliant (MPR  80%) patients;
● Odds ratio for fracture in nonpersistent (defined as 30 days
treatment gap) versus persistent patients (30 days treatment
gap); and
● Hazard ratio for fracture in non-persistent (defined as30 days
treatment gap) versus persistent patients (30 days treatment
gap).
There is no consistently applied cutoff for MPR assessment;
rather there is a continuum of compliance onto which a dichot-
omy is applied to aid analysis. As a result, the cutoff selected var-
ies between studies. Although this dichotomy of “compliant” ver-
Fig. 1 – Flow of citations through the review. Exclusion defin
case series and case studies, systematic reviews, letters, an
no subgroup—studies involving a mixed patient population
pharmacological intervention or hormone replacement therap
and/or persistence) to medication presented; fracture risk—n
adherence; language—non-English language publications. P
men and/or women aged < 45 y; this exclusion criterion wasus “noncompliant” patients may be based on an arbitrary point srather than a clinically meaningful value, 80% is generally re-
garded to be the standard cutoff point. As such, this cutoff is used
here to determine compliance versus noncompliance.
The appropriateness of pooling data was considered for each
ratio (odds or hazard) based on an assessment of the data available
and the comparability of the studies reporting the data. The min-
imum requirements for inclusion in the meta-analysis were: 1) at
least two comparable studies reporting data for the odds or hazard
ratio and compliance or persistence definition specified above;
and 2) both the ratio (odds or hazard) and the associated 95% con-
fidence interval (95% CI) for noncompliant/nonpersistent versus
compliant/persistent cohorts for each study identified. Studies
were excluded when the data were presented in such a way as to
not allow calculation of the odds or hazard ratio (i.e., risk ratio) and
where the data presented did not meet the standard compliance/
persistence definitions selected (i.e., MPR  80% vs. MPR  50%).
here absolute fracture frequencies were presented for the com-
liant/persistent and noncompliant/nonpersistent cohorts, the
dds ratio and the rate ratio (with associated 95% CIs) were calcu-
ated. The rate ratio was used as a close approximation to the
azard ratio.
A detailed description of the methodology and handling of statis-
ical heterogeneity is provided as supplementary material. In addi-
ion to assessing statistical heterogeneity, judgments about clinical
eterogeneity were qualitative and involved the evaluation of the
s included study design—randomized controlled trials,
torials; population—patient groups without osteoporosis;
out presentation of data by subgroup; intervention—non-
ly; adherence—no data relating to adherence (compliance
ta relating to fracture risk as a result of adherence/non-
ation originally involved exclusion of studies involving
xed following protocol amendment.ition
d edi
with
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s relaimilarities and differences between studies to assess the appropri-
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Study Design Interventions
received
(naïve/prior
users)
Studied
population
(% women)
Data
collection
period
Follow-up
(wks)
Fracture type Definition of compliance/
persistence
Compliance
and/or
persistence
Blouin 2008
[44]
Case-control (retrospective
claims database)
BP (naïve) 21,105 (100%) 2002 to 2005 100 (mean) Non-vertebral
fractures
MPR  80% (vs. MPR  80%) Compliance
Briesacher
2007 [27]
Cohort (retrospective
database)
BP (naïve) 17,988 (94%) 2000 to 2004 156 Wrist, hip, or
proximal
humerus
MPR  20% (vs. MPR 20%–
39%, MPR 40%–59%, MPR
60%–79%, MPR
80%–100%)
Compliance
Caro 2004*
[15]
Cohort (retrospective
database)
BP, C, HRT
(unclear)
11,249 (100%) 1996 to 2001 104 (mean) All fractures MPR  80% (vs. MPR  80%) Compliance
Cotte 2008*
[23]
Case-control (retrospective
database)
BP, Ral, SR
(naïve)
2468 (100%) 2001 to 2006 159 (mean) All fractures MPR 80% (vs. MPR 20%,
MPR 20% to 40%, MPR
40% to 60%, MPR 60% to
80%)
Time from initial
prescription to
discontinuation
(permissible gap  30 d)
Compliance 
persistence
Curtis 2008
[36]
Cohort (retrospective
claims database)
BP (naïve) 101,038 (100%) 1998 to 2005 116 (mean) All fractures MPR  80% (vs. MPR  50%) Compliance
Curtis 2007
[abstract]
[45]
Cohort (retrospective
claims database)
BP (naïve) 103,038 (NR) — — Non-vertebral
fractures
MPR  80% (vs. MPR  50%) Compliance
Davie 2007
[abstract]
[41]
Prospective cohort BP, HRT
(naïve)
254 (100%) — — Hip and wrist
fractures
5-y compliance Compliance
de Lusignan*
2006 [46]
Cross-sectional
(GP records)
BP, HRT, Ca,
Vit D,
SERM, C
(unclear)
1286 (100%) March 2005
to May
2005
— All fractures MPR  80% (vs. MPR  80%) Compliance
Feldstein
2009 [47]
Case-control (retrospective
database)
BP, C, HRT,
Ral (naïve)
3658 (100%) 1995 to 2006 140 (mean) Any closed
fracture
excluding
face, skull,
finger, or
toe
MPR  80% (vs. MPR  80%) Compliance
Gallagher
2008* [35]
Cohort (retrospective
database)
BP (naïve) 44,531 (81%) 1987 to 2006 — All fractures Current use vs. past use
(current use 0–6 mo after
starting, 6 mo after
starting, 6–24 mo after
starting, 24 mo after
starting, all vs. past use
6 mo after
discontinuation)
measured via repeat
prescription within 3 mo
after the expected end of
the previous
prescription
Persistence
Gold 2007*
[37]
Cohort (retrospective
claims database)
BP (naïve) 4769 (100%) 1996 to 2003 104 All fractures Prescription refill gap of 
30 d over 24 mo
Persistence
Gothe 2007*
[abstract]
[24]
Cohort (retrospective
database)
BP (naïve) 4451 (NR) 2000 to 2004 — All fractures MPR 80% (vs. MPR 80%)
Persistence vs.
nonpersistence defined
by the duration of
continuous therapy (no
further information)
Compliance 
Persistence
Huybrechts
2006* [16]
Cohort (retrospective
claims database)
BP, HRT
(unclear)
38,120 (100%) 1997 to 2002 88 (mean) All fractures MPR  80% (vs. MPR  80%) Compliance
ICARO Study
(Adami
2006) [48]
Cohort (retrospective) BP, Ral, Ca,
Vit D (prior
users)
880 (100%) — 104 (median) Vertebral or
non-
vertebral
fragility
fractures
MPR  75% (vs. MPR  75%) Compliance
ICARO Study
(Adami
2008) [49]
Cohort (prospective) BP, Ral, Ca,
Vit D (prior
users)
862 (100%) — 59 (mean) Vertebral or
non-
vertebral
fragility
fractures
MPR  75% (vs. MPR  75%) Compliance
Jaglal 2007*
[abstract]
[50]
Cohort (retrospective
database)
BP, SERM
(naïve)
74,085 (NR) 2002 to 2004 — All fractures MPR  80% (vs. MPR  80%)
and MPR  68% (vs. MPR
 68%)
Compliance(continued on next page)
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of clinical heterogeneity was made before conducting the meta-anal-
ysis and informed a series of sensitivity analyses whereby studies
were excluded based on differences in study design, publication type,
population size, mean follow-up period, interventions received, frac-
ture location, ratio adjustment, and persistence cut-off (further detail
is provided in the supplementary material available at: doi:10.1016/
j.jval.2010.11.010).
Results
Study flow
The flow of citations through the review is given in Figure 1. Eigh-
teen studies met the original inclusion criteria; following protocol
amendment 21 studies were included for data abstraction, and six
Table 1 (continued)
Study Design Interventions
received
(naïve/prior
users)
Studied
population
(% women)
D
col
p
Kun 2008
[abstract]
[51]
Cohort (prospective) BP (unclear) 244 (98%) 2004
McCombs
2004 [25]
Cohort (retrospective
database)
BP, Ral, HRT
(naïve)
58,109 (99%) 1998
Penning-van
Beest
2008* [42]
Cohort (retrospective
database)
BP (naïve) 8822 (100%) 1999
Perreault
2008 [52]
Case-control (retrospective
database)
BP, Ral, C
(unclear)
35,853 (100%) 1995
Rabenda
2008
[abstract]
[53]
Case-control
(retrospective)
SR (unclear) 1710 (100%)
Rabenda
2008* [26]
Case-control (retrospective
claims database)
BP (naïve) 54,807 (100%) 2001
Rietbrock
2009 [38]
Cross-sectional (GP
records)
BP (naïve) 44,531 (100%)
Siris 2006*
[14]
Cohort (retrospective
claims database)
BP (naïve) 35,537 (100%) 1999
van den
Boogaard
2006* [39]
Case-control (retrospective
database)
BP (naïve) 14,760 (100%) 1996
Weycker
2007 [54]
Case-control (retrospective
claims database)
BP, C, HRT,
Ral (naïve)
2613 (100%) 1998
Zambon
2008 [40]
Cohort (retrospective
database)
BP (naïve) 11,863 (100%) 2003
BP, bisphosphonates (alendronate, risedronate, etidronate, and/or iba
Ral, raloxifene; SERM, selective estrogen receptor modulators; SR, str
* The study was suitable for inclusion in pooled analyses; the reas
Supplementary Material.conference abstracts were identified as meeting the inclusion cri-teria. Of these 27 studies, 12 (44%) contained data suitable for at
least one of the four meta-analyses conducted. Two of the in-
cluded studies were abstracts. It was deemed appropriate to in-
clude data from abstracts to avoid potential bias in the results
(toward those studies where a stronger relationship detected al-
lowed easier full-text publication). The reasons for study exclu-
sion from the meta-analyses are presented in the supplementary
material available at: doi:10.1016/j.jval.2010.11.010. None of the
studies were excluded from the analysis based upon a qualitative
assessment of poor quality; the outcome of the quality assessment
is available upon request.
The characteristics of the 27 included studies are given in Table
1. The majority of studies were retrospective database analyses
considering adherence in new users of bisphosphonate therapy.
Twenty-three (85%) of the studies presented data relating to com-
pliance, while nine (33%) considered persistence. Five (19%) con-
Follow-up
(wks)
Fracture type Definition of compliance/
persistence
Compliance
and/or
persistence
7 — All fractures Continuation with therapy
(no further information)
Persistence
1 — Vertebral,
Colles
(lower arm
and wrist),
and hip
fractures
Total days of therapy in the
first year
Prescription refill gap of  2
wk
Compliance 
Persistence
4 — All fractures MPR  80% (vs. MPR  80%) Compliance
3 218 (mean) All fractures MPR  80% for short-,
intermediate-, and long-
term treatment
durations and MPR 
80% (vs. no treatment)
Compliance
156 Non-vertebral
fractures
MPR  80% (vs. MPR 80%) Compliance
4 40 (mean) Hip fracture MPR  80% (vs. MPR  80%)
Time from initial
prescription to
discontinuation
(permissible gap  5 wk)
Compliance 
Persistence
— Hip, vertebral,
radius,
ulna, rib,
sternum,
tibia,
fibula, and
other, non-
osteoporotic
fractures
MPR  90% (very good
compliance; vs. tertiles
 90% defined as good,
medium, and bad
compliance)
Compliance
3 104 All fractures MPR  80% (vs. MPR  80%)
Prescription refill gap of 
30 d over 24 mo
Compliance 
Persistence
3 — All fractures Prescription refill gap  1/2
the period of the given
dispensing or  7 d for 1
or 2 y
Persistence
3 — All fractures MPR  90% (vs. MPR  30%,
MPR 30%–69%, MPR
70%–89%)
Compliance
5 — All fractures Percentage of time covered
by treatment
Compliance
nate); C, calcitonin; Ca, calcium; HRT, hormone replacement therapy;
m ranelate; Vit D, vitamin D.
or study exclusion from the pooled analyses are presented in theata
lection
eriod
to 200
to 200
to 200
to 200
—
to 200
—
to 200
to 200
to 200
to 200
ndro
ontiu
ons fsidered both compliance and persistence [14,23–26]. The follow-up
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to 218 weeks, with 10 (37%) studies reporting a follow-up of 2 years
or longer. Overall, 698,631 patients were involved in the 27 studies
identified: 634,327 patients contributed to the assessment of frac-
ture and compliance and 219,676 patients contributed to the anal-
ysis of persistence.
Compliance
Twenty studies used the MPR to assess compliance and commonly
took 80% as the cutoff point at which to define compliant (MPR 
80%) and noncompliant (MPR  80%) patients (Table 1). Across
hose studies presenting the absolute fracture rates in compliant
nd non-compliant cohorts, the frequency of fracture was consid-
rably higher in non-compliant patients (Fig. 2a). Importantly, in
tudies reporting several MPR cutoff points the frequency of fracture
ppears to increase as the level of compliance decreases (Fig. 2b),
uggesting that there may not be one point at which compliance can
e dichotomized.
Eight studies were suitable for pooled comparison in the meta-
nalysis of compliance: four were included in the odds ratio anal-
sis, constituting data from 113,376 patients, and seven within the
azard ratio analysis, constituting data from 101,933 patients. The
eta-analyses suggest that noncompliance (vs. compliance) in-
reases the risk of all fractures by 28% (18%–38%) and 29% (22%–
8%) when using the hazard and odds ratios, respectively (Figs. 3a
nd 3b).
Sensitivity analysis based on study design, population size,
ublication type, intervention assessed, and ratio adjustment
Fig. 2 – Absolute fracture frequencies (%) with nonadherndicated that these variables had minimal effect on the pooledodds ratio, with fracture risk still found to be increased at be-
tween 27% and 37% in noncompliant compared to compliant
patients (Table 2). In contrast, the skeletal sites considered
within these studies do appear to be important: Rabenda et al.
[26] contained data potentially suitable for inclusion in the main
analyses but considered only hip fractures, while all other stud-
ies included in the analysis considered fractures at any location.
As a result, this study was not included in the main analysis but
was included in sensitivity analysis to determine the effect of
fracture location on the pooled result: the inclusion of Rabenda
et al. [26] reduced the fracture risk to 24% and increased the
statistical heterogeneity within the analysis.
Sensitivity analysis found that most variables had little ef-
fect on the overall risk of fracture with noncompliance based on
the hazard ratio, with the increase generally estimated at be-
tween 28% and 30% (Table 2). However, it should be noted that
exclusion of studies with fewer than 10,000 patients reduced
the estimated increase in fracture risk to 21%.
Persistence
A range of definitions have been used to assess persistence with
osteoporosis therapy in the nine studies identified (Table 1). The
most frequently utilized measure was the prescription refill
gap, where between seven and 90 days was permissible before it
was concluded that the patient was nonpersistent with therapy.
Despite the differences in the definition of persistence, it is clear
that the absolute fracture frequency is higher in the cohort
classed as nonpersistent than in patients seen to persist with
: compliance (Panels A–B) and persistence (Panels C–D).encetherapy (Fig. 2c). Further, the duration for which a patient per-
v
a
d
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longer durations of persistence are associated with a lower fre-
quency of fracture (Fig. 2d).
Five studies were suitable for pooled comparison in meta-anal-
ysis: four were included in the odds ratio analysis, constituting
data from 57,534 patients, and all five within the hazard ratio anal-
ysis, constituting data from 90,565 patients (Table 2). The pooled
analyses indicate that nonpersistence (vs. persistence) increases
the risk of all fractures by 40% (29%–52%) and 32% (23%–42%) when
using the odds and hazard ratios, respectively (Figs. 3c and 3d).
Within the meta-analysis of the odds ratio data for persistence,
the sensitivity analyses indicated that the risk of fracture with
non-persistence was only minimally affected by this clinical het-
erogeneity (Table 2). However, as discussed for compliance, only
hip fractures were included in Rabenda et al. [26]. Inclusion of this
study in the pooled hazard ratio increased the risk of fracture with
nonpersistence to 53% (16%–101%) but introduced significant sta-
tistical heterogeneity within the analysis. In contrast, the remain-
ing sensitivity analyses demonstrated that the impact of all other
variables on the pooled result was minimal (Table 2).
PMO subgroup analysis
The results of the subgroup analyses (Fig. 4) are similar to the
results of the main analyses (Fig. 3): noncompliance appears to
increase the risk of fracture in a PMO patient by 37% (95% CI
15%– 65%) and 23% (95% CI 18%–29%) when using the odds and
Fig. 3 – Meta-analysis of fracture rate with nonadherence to
rates (rate ratio calculated as a close approximation to the h
alue. #Less than 30-d treatment gap except for van den Boo
nd defined as a treatment gap of less than half the dispens
efinition of persistence was not described. The complianc
statistical heterogeneity; as such the random effects model
significant statistical heterogeneity (P > 0.05) and were analy
also contained data potentially suitable for inclusion in thes
other studies included fractures at any location. As a result,
included in sensitivity analysis to determine the affects of frhazard ratio, respectively. Nonpersistence increases the risk offracture in a PMO cohort by 40% (95% CI 29%–52%) and 36% (95%
CI 26%– 48%), when using the odds and hazard ratio, respec-
tively. Sensitivity analyses conducted on these results confirm
that the only variable to influence the associated increase in
risk with nonadherence is fracture location, where the inclu-
sion of the study focused solely on hip fracture (Rabenda et al.
[26]) reduces the association between compliance and fracture
risk and increases the association between persistence and
fracture risk (data not shown).
Direct costs and resource use
Data in the included studies relating to the risk of hospitalization
and the effect on total health care costs as a result of nonadher-
ence and fracture were limited. Patients who are nonadherent to
their prescribed therapy had both an increased risk of hospitaliza-
tion [16] and an increase in the total cost of health care incurred
[16,23,25,27]. For example, a large database study involving almost
40,000 patients reports that the risk of hospitalization increases by
approximately 50% in poorly compliant patients (MPR  50%)
when compared to highly compliant patients (MPR  90%), while
the total direct costs per month increase by 76% from $340 to $600
(MPR  80% vs. MPR  80%) [16]. This increase in hospitalization
rate and direct health care costs with nonadherence is not surpris-
ing given the results of an earlier database study that found an
increase in overall expenditure in osteoporosis patients experi-
apy in all patients. *Data calculated from absolute fracture
d ratio), +95% confidence interval (CI) calculated from P
d et al. [39], where continuous persistence was required
uration or 7 d, and Gallagher et al. [35], where the
zard ratio analysis for all patients contained significant
used for these analyses. All other analyses did not contain
using a fixed effects model. Although Rabenda et al. [26]
alyses, the study considered only hip fractures while all
study was not included in the main analyses but was
re location on the pooled result.ther
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fracture compared to patients without.
Discussion
This systematic review and meta-analysis of observational stud-
ies provides the first focused quantitative summary and compar-
ison of fracture risk in patients who are adherent versus patients
who are nonadherent to treatment with osteoporosis medication.
Our analysis indicates that the risk of fracture is increased by ap-
proximately 30% with noncompliance (MPR 80%) and by approx-
mately 30% to 40% with nonpersistence (discontinuation before 2
ears of therapy) when compared to the risk of fracture in com-
liant and persistent patients, respectively. The associated risk
ppears to be similar across all patients and within a subgroup
f PMO patients.
The results presented here are in agreement with the results of
he qualitative review conducted recently by Siris et al. [17], where
he importance of adherence for therapeutic benefit and reduction
f clinical and economic burden was emphasized, and are similar
o the 46% increase in fracture risk with noncompliance to bisphos-
honates reported recently [19]. It should be noted that there are
mportant differences between the analysis presented here and
hat reported by Imaz et al. [19]. First, our review was designed
pecifically to identify all studies presenting fracture risk and ad-
erence data, while the Imaz publication [19] was primarily fo-
used on quantifying level of adherence to bisphosphonates
hrough an update of two previous systematic reviews focused on
dherence to treatment [13,29]. Secondly, Imaz et al. [19] restrict
their analysis to the consideration of compliance, and use only
Cox proportional hazard ratio or conditional logistic regression
data from the studies included. While this gives an indication of
Table 2 – Sensitivity analysis results.
Factor Study
Compliance OR
Study design* de Lusignan 2006 [46]
Fracture location* Rabenda 2008 [26]†
Population size de Lusignan 2006 [46] an
Intervention Cotte 2008 [23] and Jagla
Unadjusted ratio/publication type Jaglal 2007 [50]
Compliance HR
Study design* de Lusignan 2006 [46]
Population size Penning van-Beest 2008
[24], and de Lusignan 2
Unadjusted ratio Huybrechts 2006 [16], Pen
2004 [15], and Gothe 20
Intervention Huybrechts 2006 [16], Co
Publication type Gothe 2007 [24]
Persistence OR
Population size Gold 2007 [37] and Cotte
Intervention Cotte 2008 [23]
Persistence cut-off point Gold 2007 [37]
Persistence HR
Fracture location* Rabenda 2008 [26]†
Population size Cotte 2008 [23] and Gold
Interventions received Cotte 2008 [23]
Persistence cut-off
point/unadjusted ratio
Gallagher 2008 [35] and G
OR, odds ratio; HR, hazard ratio; CI, confidence interval.
* A random effects analysis was conducted due to the presence of s
model.
† Sensitivity analysis involved the inclusion (rather than exclusion)the increase in fracture risk with nonadherence, by consideringseparately the odds ratio and the hazard ratio for both compliance
and persistence, our analysis provides a more complete picture of
the association between adherence and fracture risk. Indeed, the
fact that all four analyses provide a similar estimate of increased
fracture risk with nonadherence compared to adherence supports
the robustness of the quantitative estimates produced. Finally, our
meta-analysis has been driven by robust statistical methodology.
For example, the Mantel-Haenszel method of study weighting was
specifically selected because this was designed to be used in meta-
analyses combining ratio data [30]. Similarly, in pooling data
across studies we have been careful to select only data arising
from studies that can be considered sufficiently homogeneous as
to be estimating the same effect and thus provide a meaningful
overall estimate of risk when combined. For example, studies de-
fining compliance and non-compliance using nonstandard MPR
cutoffs were excluded from the pooled analysis (MPR  30% and
MPR  50%). Our review thus provides an important and robust
quantitative estimate of the importance of adherence to osteopo-
rosis medication in maximizing clinical benefit.
Potential limitations of this meta-analysis include clinical
heterogeneity among the studies. An important source of this
heterogeneity is the location of the fracture that is the outcome
measure. For example, in two of the included studies the asso-
ciation of increased risk of fracture with nonadherence is sig-
nificant for vertebral fracture but not for wrist and forearm frac-
ture [23,25]. Fractures of the hip may also be affected by
nonadherence to a larger degree than other fracture locations
[14,25,26]. Given the high degree of clinical burden associated
with both vertebral and hip fracture, this finding is of particular
importance and may deserve further attention from a clinical
management perspective. A second source of heterogeneity be-
tween studies may relate to the fracture history of the included
lusion OR/HR (95% CI) P
1.341 (1.143–1.574) 0.001
1.238 (1.038–1.478) 0.018
te 2008 [23] 1.268 (1.188–1.355) 0.001
[50] 1.282 (1.196–1.375) 0.001
1.316 (1.232–1.406) 0.001
1.291 (1.181–1.411) 0.001
otte 2008 [23], Gothe 2007
46]
1.212 (1.156–1.271) 0.001
van-Beest 2008 [42], Caro
4]
1.276 (1.199–1.359) 0.001
08 [23], and Caro 2004 [15] 1.299 (1.224–1.378) 0.001
1.229 (1.175–1.285) 0.001
[23] 1.397 (1.275–1.531) 0.001
1.386 (1.270–1.512) 0.001
1.410 (1.292–1.538) 0.001
1.526 (1.159–2.011) 0.003
[37] 1.312 (1.215–1.416) 0.001
1.314 (1.220–1.416) 0.001
007 [37] 1.364 (1.255–1.483) 0.001
cant statistical heterogeneity, all other analyses use a fixed effects
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of fracture with nonadherence.
There are limitations to the measures employed by included
studies to measure compliance. It is widely recognized that the
presence of a refill prescription does not necessarily mean that the
patient was taking the medication as prescribed [13]. Further,
some claims database analyses consider patients who switch pro-
viders or whose clinician terminated the prescription as having
poor adherence [31]. Similarly, patients who show a treatment gap
of greater than 30 days (or any alternative persistence definition)
may continue or restart therapy following their categorization as
nonpersistent. However, these biases are likely to attenuate the
effect of poor adherence on fracture risk, by including potentially
adherent patients within the non-adherent patient group. It has
also been recognized that patient-reported compliance and per-
sistence, the alternative to database analyses, is limited by inac-
curacies [32], resulting from a reluctance to report noncompliance
nd nonpersistence and/or recall bias [33,34]. Thus refill compli-
ance and persistence can be considered as useful measures of
adherence in the absence of a feasible alternative [17,31].
Publication bias is another potential limitation of this review.
he implication of this bias is that small studies detecting no re-
ationship between adherence and fracture risk may not have
een published, as was suggested by Imaz et al. [19] for their anal-
sis of all site fracture risk. However, given the broader search, the
arge sample size of the majority of studies included in our review,
Fig. 4 – Meta-analysis of fracture rate with nonadherence to
calculated from absolute fracture rates (rate ratio calculated
interval (CI) calculated from P. †Less than 30 d treatment gap
ersistence was required and defined as a treatment gap of
l. [35], where the definition of persistence was not describe
atients with osteoporosis contained significant statistical h
hese analyses. All other analyses did not contain significan
xed effects model. Although Rabenda et al. [26] also contai
he study considered only hip fractures, while all other stud
as not included in the main analyses but was included in
n the pooled result.nd the more conservative estimate of the association of adher- ince and fracture risk, publication bias may be considered to be
inimal and to have a low effect on the conclusions drawn.
Study design bias is another potential limitation of the meta-
nalysis, given that many of the included studies used retrospec-
ive database analyses. Although most studies controlled for the
mpact of confounding factors such as age, sex, bone mineral den-
ity, prior medications, and fracture history in adjusted analyses,
he confounding factors selected were not consistent across stud-
es. As a result of this heterogeneity the unadjusted results, where
vailable, were selected for inclusion into our meta-analysis. This
act should be considered when interpreting the results and ap-
lying them to the osteoporotic population as a whole. Despite
hese limitations, the observational study design is recognized to
ave greater external validity than a randomized controlled trial
nd thus the results are more easily generalizable to the whole
opulation with osteoporosis. Further, the studies tended to be
omparable in terms of study design (mainly retrospective data-
ase analyses), treatments received (largely restricted to bisphos-
honates), and fracture location (generally all fractures were con-
idered).
Although predictors of poor adherence to osteoporosis treat-
ents were of interest in this review, many of the included studies
id not directly consider this. From the studies that did consider
isk factors, several variables arise as clear predictors of adherence
o therapy. Patients of younger age appear to be less adherent to
edication than older patients [14,25,35,36], while treatment reg-
apy in a post-menopausal osteoporosis cohort. *Data
close approximation to the hazard ratio), +95% confidence
ept for van den Boogaard et al. [39], where continuous
than half the dispensing duration or 7 d, and Gallagher et
he compliance odds ratio analysis for postmenopausal
ogeneity; as such the random effects model was used for
tistical heterogeneity (P > 0.05) and were analyzed using a
ata potentially suitable for inclusion in these analyses,
ncluded fractures at any location. As a result, this study
itivity analysis to determine the effect of fracture locationther
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580 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 5 7 1 – 5 8 1with poor adherence to therapy [26,35,37–40]. The length of time
from treatment initiation may also be important [16,41,42]. Given
the clinical importance of adherence to osteoporosis therapy ob-
served in the current review, future research should focus on de-
termining further the factors that underlie poor adherence and
how adherence might be increased. This may involve the devel-
opment of therapies with less frequent administration alongside
research into new management programs for improving adher-
ence. It should also be recognized that the relationship between
adherence and fracture rate may reflect the fact that an adherent
individual is more likely to lead a healthier lifestyle and to exert
greater care to avoid activities that could increase the likelihood of
sustaining a fracture [43].
A final important consideration is the economic implication of
oor adherence. The, albeit limited, data reported in the studies in
his review suggest that the direct cost of poor adherence is sig-
ificant. However, this area warrants further, specific research to
uantify the effect of poor compliance and persistence on frac-
ure-related resource use and costs.
Conclusions
This systematic review highlights the importance of compliance
and persistence to medications known to be effective in the treat-
ment of osteoporosis. Poor adherence is associated with a signifi-
cantly increased risk of fracture. Given that one-third to one-half
of patients do not take their medication as directed [13], the addi-
tional burden on society due to nonadherence is likely to be high.
Enhancing both compliance and persistence to osteoporosis ther-
apy could significantly reduce the burden of osteoporosis in terms
of fracture frequency, hospitalizations, and direct medical costs.
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